Narjust Florez MD, Sandip Patel MD, Heather A. Wakelee MD, Julia Rotow MD, Elaine Shum MD, Jacob Sands MD, Ravi Salgia MD, PhD, Fred R. Hirsch MD, PhD, Solange Peters MD, PhD, Joshua Sabari MD, Hatim Husain MD, Lyudmila Bazhenova MD, Erminia Massarelli MD, PhD, MS, Leah M. Backhus MD, MPH, Percy Lee MD, Roy S. Herbst MD, PhD, Christine Bestvina MD, Kristin Higgins MD, Aakash Desai MD, MPH, Martin Dietrich MD, PhD, Hari Balaji Keshava MD, MS, Balazs Halmos MD, MS, David R. Gandara MD, Jonathan Wesley Riess MD, MS, Ana I. Velázquez MD, MSc, Anjali Sibley MD, MPH, Misty Shields MD, PhD, Triparna Sen PhD, MS, Edward S. Kim MD, MBA
{"title":"肺癌管理的临床策略：来自2024年弥合差距肺癌共识会议的建议","authors":"Narjust Florez MD, Sandip Patel MD, Heather A. Wakelee MD, Julia Rotow MD, Elaine Shum MD, Jacob Sands MD, Ravi Salgia MD, PhD, Fred R. Hirsch MD, PhD, Solange Peters MD, PhD, Joshua Sabari MD, Hatim Husain MD, Lyudmila Bazhenova MD, Erminia Massarelli MD, PhD, MS, Leah M. Backhus MD, MPH, Percy Lee MD, Roy S. Herbst MD, PhD, Christine Bestvina MD, Kristin Higgins MD, Aakash Desai MD, MPH, Martin Dietrich MD, PhD, Hari Balaji Keshava MD, MS, Balazs Halmos MD, MS, David R. Gandara MD, Jonathan Wesley Riess MD, MS, Ana I. Velázquez MD, MSc, Anjali Sibley MD, MPH, Misty Shields MD, PhD, Triparna Sen PhD, MS, Edward S. Kim MD, MBA","doi":"10.1002/cncr.70060","DOIUrl":null,"url":null,"abstract":"<p>Clinical practice guidelines for nonsmall cell lung cancer (NSCLC) and small cell lung cancer include recommendations based on high-level clinical trial evidence, but complex clinical questions are frequently seen in real-world practice that are not clearly answered by prospective trial data. To address these questions, the <i>Bridging the Gaps Lung Cancer Consensus Conference 2024</i> (BtG LCCC 2024) convened to develop US-focused expert guidance for clinical situations in which level 1 evidence is lacking. At BtG LCCC 2024, a multidisciplinary expert panel discussed ongoing clinical issues in small cell lung cancer management, targeted therapy in <i>EGFR</i>-mutated NSCLC, management of early stage NSCLC, identification and management of non-<i>EGFR</i> oncogene-driven NSCLC, and use of immunotherapy in advanced/metastatic NSCLC. By using a modified Delphi process, 12 consensus recommendations were developed with the goal of providing guidance on the use of novel diagnostic methods and treatments for clinicians who manage lung cancer. This report reviews these areas of consensus and discusses ongoing questions about ways to apply current clinical evidence.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024\",\"authors\":\"Narjust Florez MD, Sandip Patel MD, Heather A. Wakelee MD, Julia Rotow MD, Elaine Shum MD, Jacob Sands MD, Ravi Salgia MD, PhD, Fred R. Hirsch MD, PhD, Solange Peters MD, PhD, Joshua Sabari MD, Hatim Husain MD, Lyudmila Bazhenova MD, Erminia Massarelli MD, PhD, MS, Leah M. Backhus MD, MPH, Percy Lee MD, Roy S. Herbst MD, PhD, Christine Bestvina MD, Kristin Higgins MD, Aakash Desai MD, MPH, Martin Dietrich MD, PhD, Hari Balaji Keshava MD, MS, Balazs Halmos MD, MS, David R. Gandara MD, Jonathan Wesley Riess MD, MS, Ana I. Velázquez MD, MSc, Anjali Sibley MD, MPH, Misty Shields MD, PhD, Triparna Sen PhD, MS, Edward S. Kim MD, MBA\",\"doi\":\"10.1002/cncr.70060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Clinical practice guidelines for nonsmall cell lung cancer (NSCLC) and small cell lung cancer include recommendations based on high-level clinical trial evidence, but complex clinical questions are frequently seen in real-world practice that are not clearly answered by prospective trial data. To address these questions, the <i>Bridging the Gaps Lung Cancer Consensus Conference 2024</i> (BtG LCCC 2024) convened to develop US-focused expert guidance for clinical situations in which level 1 evidence is lacking. At BtG LCCC 2024, a multidisciplinary expert panel discussed ongoing clinical issues in small cell lung cancer management, targeted therapy in <i>EGFR</i>-mutated NSCLC, management of early stage NSCLC, identification and management of non-<i>EGFR</i> oncogene-driven NSCLC, and use of immunotherapy in advanced/metastatic NSCLC. By using a modified Delphi process, 12 consensus recommendations were developed with the goal of providing guidance on the use of novel diagnostic methods and treatments for clinicians who manage lung cancer. This report reviews these areas of consensus and discusses ongoing questions about ways to apply current clinical evidence.</p>\",\"PeriodicalId\":138,\"journal\":{\"name\":\"Cancer\",\"volume\":\"131 17\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70060\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70060","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Clinical practice guidelines for nonsmall cell lung cancer (NSCLC) and small cell lung cancer include recommendations based on high-level clinical trial evidence, but complex clinical questions are frequently seen in real-world practice that are not clearly answered by prospective trial data. To address these questions, the Bridging the Gaps Lung Cancer Consensus Conference 2024 (BtG LCCC 2024) convened to develop US-focused expert guidance for clinical situations in which level 1 evidence is lacking. At BtG LCCC 2024, a multidisciplinary expert panel discussed ongoing clinical issues in small cell lung cancer management, targeted therapy in EGFR-mutated NSCLC, management of early stage NSCLC, identification and management of non-EGFR oncogene-driven NSCLC, and use of immunotherapy in advanced/metastatic NSCLC. By using a modified Delphi process, 12 consensus recommendations were developed with the goal of providing guidance on the use of novel diagnostic methods and treatments for clinicians who manage lung cancer. This report reviews these areas of consensus and discusses ongoing questions about ways to apply current clinical evidence.
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
